Jacques Dumas is Chief ScientificOfficer at TETRAPHASE PHARMACEUTICALS INC (TTPH). They have made 3 open-market trades across 1 company since 2017, most recently 2019-01-08.
CIK 0001598640
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TTPH | 8,750 | $19K |
Shares reported on the most recent Form 4, priced at the 2018-01-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TTPH | SELL · 10b5-1 | 2019-01-08 | 2019-01-10 | $1.60 | $12K | -23.5% | -18.8% | -15.4% |
| TTPH | SELL | 2018-01-30 | 2018-01-31 | $6.22 | $54K | -6.3% | -54.7% | -44.3% |
| TTPH | SELL · 10b5-1 | 2018-01-09 | 2018-01-11 | $6.21 | $45K | -3.8% | -16.6% | -53.0% |
| TTPH | SELL | 2017-10-31 | 2017-11-02 | $6.03 | $106K | +1.4% | +1.4% | -1.4% |
| TTPH | SELL | 2017-08-22 | 2017-08-24 | $6.00 | $105K | +5.9% | +4.5% | +4.2% |
| TTPH | SELL · 10b5-1 | 2017-08-17 | 2017-08-21 | $5.86 | $42K | +22.5% | +22.6% | +11.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.